Emapalumab (anti-IFNγ)

Emapalumab (anti-IFNγ), a monoclonal antibody directed against IFNγ, is the first global approval for the treatment of pediatric and adult patients with primary hemophagocytic lymphohistiocytosis (HLH) with refractory.
Supplier Selleck Chemicals
Product # A2041
Sku # A2041-1mg*5
Pricing 1mg*5, $777.00
Feedback